Projects per year
Fingerprint
Dive into the research topics where Thomas Elmer Witzig is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 11 Finished
-
Project 3: Targeting Tumor Metabolism in Lymphoma
Bishop, G. A. (PI) & Witzig, T. E. (PI)
9/1/17 → 6/30/22
Project: Research project
-
Signal transduction inhibitor therapy for Lymphoma
Witzig, T. E. (CoPI) & Witzig, T. E. (PI)
9/20/07 → 7/31/14
Project: Research project
-
PI3K Pathway Inhibitors for Mantle Cell Lymphoma
Witzig, T. E. (PI)
8/18/05 → 7/31/06
Project: Research project
-
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer
Weiner, G. J. (PI), Ballas, Z. K. (CoPI), Bishop, G. A. (CoPI), Cerhan, J. R. (CoPI), Dogan, A. M. (CoPI), Farooq, U. (CoPI), Feldman, A. L. (CoPI), Gupta, M. D. (CoPI), Habermann, T. M. (CoPI), Hohl, R. J. (CoPI), Houtman, J. C. D. (CoPI), Juweid, M. E. (CoPI), Kaufmann, S. H. (CoPI), Lentz, S. R. (CoPI), Link, B. K. (CoPI), Macon, W. R. (CoPI), Ratliff, T. L. (CoPI), Smith, B. J. (CoPI), Ansell, S. M. (CoPI), Syrbu, S. (CoPI), Geyer, S. S. M. (CoPI) & Witzig, T. E. (CoPI)
9/11/02 → 6/30/22
Project: Research project
-
P4 - Regulatory T-Cells in the Tumor Microenvironment of B-Cell Non-Hodgkin
Witzig, T. E. (PI), Ansell, S. M. (PI) & Ansell, S. M. (PI)
10/1/01 → 6/30/12
Project: Research project
-
Defining primary refractory large B-cell lymphoma
Bock, A. M., Mwangi, R., Wang, Y., Khurana, A., Maurer, M., Ayers, A., Kahl, B. S., Martin, P., Cohen, J. B., Casulo, C., Lossos, I. S., Farooq, U., Ayyappan, S., Reicks, T., Habermann, T. M., Witzig, T. E., Flowers, C. R., Cerhan, J. R., Nastoupil, L. J. & Nowakowski, G. S., Jul 9 2024, In: Blood Advances. 8, 13, p. 3402-3415 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach
Le, K., Vollenweider, J., Han, J. J., Staudinger, N., Stenson, M., Bayraktar, L., Wellik, L. E., Maurer, M. J., McPhail, E. D., Witzig, T. E. & Gupta, M., Jan 2024, In: Hematological Oncology. 42, 1, e3233.Research output: Contribution to journal › Article › peer-review
-
Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma
Rice, M. L., Barreto, E. F., Rule, A. D., Martin, C. E., Truong, H. L., Mara, K. C., Kashani, K. B., Thompson, C. A., Witzig, T. E. & Barreto, J. N., Jan 2024, In: Pharmacotherapy. 44, 1, p. 4-12 9 p.Research output: Contribution to journal › Article › peer-review
-
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments
Krull, J. E., Wenzl, K., Hopper, M. A., Manske, M. K., Sarangi, V., Maurer, M. J., Larson, M. C., Mondello, P., Yang, Z. Z., Novak, J. P., Serres, M., Whitaker, K. R., Villasboas Bisneto, J. C., Habermann, T. M., Witzig, T. E., Link, B. K., Rimsza, L. M., King, R. L., Ansell, S. M. & Cerhan, J. R. & 1 others, , Mar 19 2024, In: Cell Reports Medicine. 5, 3, 101443.Research output: Contribution to journal › Article › peer-review
Open Access -
Misleading Medical Stamps: The 2022 “Monkeypox” Issues
Steensma, D. P. & Witzig, T. E., Jan 2024, In: Mayo Clinic proceedings. 99, 1, p. 179-180 2 p.Research output: Contribution to journal › Comment/debate › peer-review